Brian McGee, MD
Psychiatry · Baton Rouge, LANPI 1801231329
Payments from drug & device makers
Across 187 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$836
- Otsuka America Pharmaceutical, Inc.$677
- Johnson & Johnson$527
- Teva Pharmaceuticals USA, Inc.$447
- Lundbeck LLC$150
- Neurocrine Biosciences, Inc.$130
- plus $649 from 15 others
What the payments were for
- Food & beverage$3,37799%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 50 | $836 |
| Otsuka America Pharmaceutical, Inc. | 42 | $677 |
| Johnson & Johnson | 26 | $527 |
| Teva Pharmaceuticals USA, Inc. | 29 | $447 |
| Lundbeck LLC | 8 | $150 |
| Neurocrine Biosciences, Inc. | 4 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $123 |
| Supernus Pharmaceuticals, Inc. | 2 | $105 |
| AbbVie(2 entities) | 4 | $69 |
| Vanda Pharmaceuticals Inc. | 2 | $59 |
| Corium, LLC | 2 | $44 |
| Shire North American Group Inc | 2 | $42 |
| Bausch Health US, LLC | 2 | $34 |
| Brainsway USA Inc | 1 | $28 |
| Sage Therapeutics, LLC | 1 | $27 |
| Bioxcel Therapeutics, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Abbott | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Braeburn Inc. | 1 | $16 |
How this compares
$3,416 in reported general payments places this provider in the 80th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 24 | $3,358 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 31 | $2,085 |
| Aripiprazole | 24 | $1,250 |
| Hydroxyzine Pamoate | 41 | $1,031 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $808 |
| Prazosin Hcl | 42 | $679 |
| Bupropion XlBupropion Hcl | 31 | $574 |
| Duloxetine Hcl | 42 | $423 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $371 |
| Mirtazapine | 33 | $362 |
| Alprazolam | 68 | $309 |
| Fluoxetine Hcl | 35 | $275 |
| Sertraline Hcl | 30 | $262 |
| Lorazepam | 34 | $216 |
| Hydroxyzine Hcl | 12 | $158 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Baton Rouge
- Larry WarnerBaton Rouge$495K
- Abdul KhanBaton Rouge$156K
- Donna FargasonBaton Rouge$11K
- Aniedi UdofaBaton Rouge$9K
- Sudheera RachamalluBaton Rouge$7K
- Jason BoudreauxBaton Rouge$5K
- Kashinath YadalamLake Charles$3.8M
- Guy BrannonShreveport$1.4M
- Patrick HayesLake Charles$853K
- Maria CruseThibodaux$522K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.